Trade with Eva: Analytics in action >>

Tuesday, April 1, 2025

Bitcoin ETFs

Charts:

TickerIssuerETF NameTypeMarket cap
IBITBlackRockiShares Bitcoin TrustSpot$47.43B
FBTCFidelityWise Origin Bitcoin Trust by FidelitySpot$16.23B
GBTCGrayscaleGrayscale Bitcoin TrustSpot$15.95B
BTCGrayscaleGrayscale Bitcoin Mini TrustSpot$3.47B
ARKBArk/21 SharesArk/21 Shares Bitcoin TrustSpot$3.93B
BITBBitwiseBitwise Bitcoin ETPSpot$3.13B
BITOProSharesProShares Bitcoin Strategy ETFFutures$1.99B
HODLVanEckVanEck Bitcoin TrustSpot$1.18B
BRRRValkyrieValkyrie Bitcoin FundSpot$488.63M
BTCOInvesco/GalaxyInvesco Galaxy Bitcoin ETFSpot$435.77M
EZBCFranklin TempletonFranklin Bitcoin ETFSpot$408.35M
BTCWWisdomTreeWisdomTree Bitcoin TrustSpot$183.69M
ARKAArk/21 SharesARK 21Shares Active Bitcoin Futures Strategy ETFFutures$9.17M
DEFIHashdexHashdex Bitcoin Futures ETFFutures$13.07M
BITCBitwiseBitwise Bitcoin Strategy Optimum Yield ETFFutures$13.26M
ARKCArk/21 SharesARK 21Shares Active On-Chain Bitcoin Strategy ETFFutures$2.04M
BETHProSharesProShares Bitcoin & Ether Market Cap Weight Strategy ETFFutures-
BTFValkyrieValkyrie Bitcoin and Ether Strategy ETFFutures-
PBTCPando AssetPando Asset Spot Bitcoin TrustSpot-
BITSGlobal XGlobal X Blockchain & Bitcoin Strategy ETFFutures-
ARKYArk/21 SharesARK 21Shares Active Bitcoin Ethereum Strategy ETFFutures-
XBTFVanEckVanEck Bitcoin Strategy ETFFutures-
BETEProSharesProShares Bitcoin & Ether Equal Weight Strategy ETFFutures-

Charts by volume (21):

IBIT - iShares Bitcoin Trust Beneficial Interest - Stock Price Chart BITO - ProShares Bitcoin ETF - Stock Price Chart FBTC - Fidelity Wise Origin Bitcoin Fund Beneficial Interest - Stock Price Chart BITB - Bitwise Bitcoin ETF Beneficial Interest - Stock Price Chart GBTC - Grayscale Bitcoin Trust - Stock Price Chart BTC - Grayscale Bitcoin Mini Trust ETF - Stock Price Chart ARKB - ARK 21Shares Bitcoin ETF Beneficial Interest - Stock Price Chart HODL - VanEck Bitcoin Trust Beneficial Interest - Stock Price Chart EZBC - Franklin Templeton Digital Holdings Trust Beneficial Interest - Stock Price Chart BRRR - Coinshares Valkyrie Bitcoin Fund Beneficial Interest - Stock Price Chart BTCW - WisdomTree Bitcoin Fund Beneficial Interest - Stock Price Chart BTCO - Invesco Galaxy Bitcoin ETF Beneficial Interest - Stock Price Chart BTF - CoinShares Valkyrie Bitcoin and Ether Strategy ETF - Stock Price Chart BITC - Bitwise Trendwise Bitcoin and Treasuries Rotation Strategy ETF - Stock Price Chart BITS - Global X Blockchain & Bitcoin Strategy ETF - Stock Price Chart BETH - ProShares Bitcoin & Ether Market Cap Weight ETF - Stock Price Chart BETE - ProShares Bitcoin & Ether Equal Weight ETF - Stock Price Chart ARKA - ARK 21Shares Active Bitcoin Futures Strategy ETF - Stock Price Chart DEFI - Hashdex Bitcoin ETF - Stock Price Chart ARKC - ARK 21Shares Active On-Chain Bitcoin Strategy ETF - Stock Price Chart ARKY - ARK 21Shares Active Bitcoin Ethereum Strategy ETF - Stock Price Chart


Thursday, March 27, 2025

ADMA Biologics (ADMA)

ADMA Biologics makes human-derived immunoglobulin. Its products treat people whose bodies don't make enough antibodies to ward off illnesses from common viruses. Instead of risking illness, people with primary immunodeficiency receive regular infusions of ADMA's drugs.
  • Sector: Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 685
  • Founded by Adam S. Grossman and Jerrold B. Grossman in 2004  
  • Headquartered in Ramsey, New Jersey
  • https://www.admabiologics.com/
IPO: October 17, 2013







ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. 


ADMA's biggest moneymaker, Asceniv. 
ADMA Biologics developed Asceniv in-house. It's a cocktail created from super donors whose plasma has a high level of antibodies capable of handling respiratory syncytial virus, or RSV. RSV leads to cold symptoms in most people, but it can be serious in people with compromised immune systems.

Last year, Asceniv generated $216.7 million in sales. This year, it's expected to bring in $283 million, growing almost 31%. Earnings are also promising. In 2024, ADMA Biologics earned 49 cents per share, flipping from no earnings in the year-earlier period. This year, it's expected to notch a 71-cent profit, up 45%.

Asceniv accounts for slightly more than half of ADMA's total sales. The company also sells Bivigam and Nabi-HB, two products it acquired. Bivigam provides various antibodies found in a healthy immune system, while Nabi-HB protects against hepatitis B in people who've been exposed.